linjc16/ctgov huggingface dataset:
Detection of Lymphnodes Using ICG During RARP

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate, whether the detection of lymph nodes by means of intraoperative fluorescence lymphography as part of lymphadenectomy in robot-assisted radical prostatectomy is higher than without the use of indocyanine green (ICG).

Detailed Description
-----------------
ICG is a fluorescent dye that fluoresces green bound to proteins under illumination in the near-infrared range. Using this dye allows to visualize lymphatic nodes, by being injected into the tumor or directly surrounding tissue.

Official Title
-----------------
Detection of Lymph Nodes by Means of Intraoperative Fluorescence Lymphography Using Indocyanine Green (ICG) During the Radical Robot-assisted Prostatectomy

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Procedure: ICG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed locally limited prostate cancer; Intermediate or high risk tumor Recommended and planned prostatectomy; Completed and signed written consent; Voluntarily agreement to participate in this study Age of the study participants ≥ 18 years. Exclusion Criteria: Allergic reaction to active ingredient (indocyanine green); Iodine allergy; Hyperthyroidism; High-grade renal impairment; High-grade hepatic insufficiency; Unwillingness to the storage and disclosure of pseudonymous disease and personal data psychiatric pre-existing conditions or other circumstances that make a cooperation by the patient in question

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Lymphadenectomy using standard Methods<br>Lymphadenectomy will be performed as a standard procedure | |
| Experimental: Lymphadenectomy using ICG<br>A fluorescent dye (indocyanine green) will be ultrasound-controlled preoperatively injected in the prostate. During robot-assisted radical intervention by DaVinci ® robot the lymphadenectomy is performed using the fluorescence lymphography. | Procedure: ICG<br>* Improvement of detection of positive lymphnodes<br>* Other names: Pulsion Medical Systems, München, Germany;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The total number of detection rate of (positive) lymph nodes using ICG |  | during the surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurements of the time, that takes to remove the lymph nodes |  | During the surgery |
the Effect of Simple Clinical Maneuver on Shoulder and Abdominal Pain a Laparascopic Gynecological Surgery:a Prospective Randomised Trial

Study Overview
=================
Brief Summary
-----------------
The investigators think that a simple maneuver at laparascopic surgery to reduce the postoperative pain.

Conditions
-----------------
Effect of CO2 Was Removed by Means Trandelenburg Position at Laparascopic Surgery

Intervention / Treatment
-----------------
* Behavioral: CO2 was removed by means of trandelenburg positions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: females aged 15-65 years, American Society of Anesthesiologists (ASA) physical status classification I-III no previous laparotomy(major abdominal surgery). need a laparascopic surgery Exclusion Criteria: required hospitalization after the laparoscopic surgery, the procedure required conversion to laparotomy if a 48-hour follow-up was not feasible

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: maneuver group<br>In the intervention group, CO2 was removed by means of Trendelenburg position (30 degrees) and a pulmonary recruitment maneuver consisting of five manual inflations of the lung. | Behavioral: CO2 was removed by means of trandelenburg positions<br> <br> |
| No Intervention: clasical group<br>no additional action will be taken after the operation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative 12. hour VAS pain score |  | 12 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative analgesic requırements |  | 48 hours |
Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation

Study Overview
=================
Brief Summary
-----------------
This study is designed to assess the hypothesis that the lipopolysaccharide (LPS) activity index can be quantified early after transplantation, as well as the the PhosphoLipid Transfer Protein (PLTP) activity and these both biological variables are independent variables for predicting the risk of severe Graft versus Host Disease (GVHD).

Official Title
-----------------
Study of Lipopolysaccharide Metabolism for Identification of New Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation

Conditions
-----------------
Hematologic Diseases, Stem Cell Transplantation

Intervention / Treatment
-----------------
* Other: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hematologic malignancy in complete remission Patients eligible for allogeneic hematopoietic cell transplantation from a related or unrelated donor and after myeloablative or non-myeloablative conditioning. Regular follow-up in the center Exclusion Criteria: Treatment with a statin in progress Umbilical cord blood transplantation Hemoglobin level less than or equal to 8g / dl Known chronic inflammatory bowel disease or gastroenteritis at the time of inclusion. Chronic enteropathy with Clostridium Difficile

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: All patients<br> | Other: Blood sample<br>* blood samples (4 times; 14ml per visit)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the ROC curve for PLTP in the occurrence of GVHD | Area under the ROC curve (AUCROC) for PLTP assessed at day 0 (day of transplantation) in the occurrence of GVHD (grade II-IV) at 3 months post-transplant. | 3 months | 
| Area under the ROC curve for LPS in the occurrence of GVHD | Area under the ROC curve (AUCROC) for LPS assessed at day 0 (day of transplantation) in the occurrence of GVHD (grade II-IV) at 3 months post-transplant. | 3 months |
Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to measure the safety of the investigational imaging agent, 18F-Var3 and to determine if it is helpful in providing information about how tumor tissues behave.

Official Title
-----------------
Phase 1 Study Using First-in-Human Acidosis Imaging With [18F]AlF-cysVar3 pHLIP® (18F-Var3) in Patients With Breast Cancer for Determination of Safety, Biodistribution and Radiation Dosimetry

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: F-Var3 PET/CT
* Other: Blood draw


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or greater Biopsy-proven breast malignancy >/= 1 viable lesion, >/= 1 cm, confirmed on CT, MR, or FDG PET/CT within 4 weeks of protocol enrollment Newly diagnosed or recurrent disease, on or off therapy ECOG performance of 0-2 *Note: Lesions are considered viable if they are stable or increasing soft tissue lesions, or if they are FDG-avid bone lesions Exclusion Criteria: Life expectancy < 3 months Pregnancy or lactation Biopsy or other surgical procedures within 48 hours prior to receiving study intervention Patients who cannot undergo PT/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 400 pounds

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Breast Cancer<br>Breast cancer | Diagnostic Test: F-Var3 PET/CT<br>* Participants will undergo up to 5 serial F-Var3 PET/CT scans within 25 minutes of the injection of 18F-Var3, 30, 60, 120 and 240 minutes after injection of the 18FVar3.<br>Other: Blood draw<br>* Collection of blood for research tests before the injection, 30, 60, 120 and 240 min after the injection.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0 | The safety of patients will be evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Grade 1 and grade 2 toxicities are considered safe. | 30 days after completion of study treatment and assessments | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast Cancer, 18F-Var3, First in human, Acidosis imaging, Memorial Sloan Kettering Cancer Center, 19-147
Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379)

Study Overview
=================
Brief Summary
-----------------
The clinical study evaluates the safety of montelukast and compares montelukast to ketotifen, used as a control drug, in terms of improvement in morning peak expiratory flow (am pef) over first 2 weeks in patients with pediatric bronchial asthma aged 6 to < 15. The effect of body weight on the efficacy and safety of montelukast will also be evaluated in this study.

Official Title
-----------------
Montelukast, on Pediatric Bronchial Asthma in Multicenter Comparative Double-Blind Clinical Study (Phase IV) With Ketotifen Fumarate

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: MK0476, montelukast sodium / Duration of Treatment: 4 Weeks
* Drug: Comparator: ketotifen / Duration of Treatment: 4 Weeks


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Intermittent asthma, mild persistent asthma, moderate persistent asthma, or severe persistent asthma patients with 2 or more mild or moderate attacks at baseline Exclusion Criteria: Patient using anti-asthma treatment or therapy including corticosteroids or oral anti-allergic drugs Patient with complications that will impair the judgment of efficacy of this drug Patient with convulsive disorders such as epilepsy or such a history Patient with liver disease, renal impairment, heart disease or such other complication

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0476, montelukast sodium / Duration of Treatment: 4 Weeks|nan|
|Drug: Comparator: ketotifen / Duration of Treatment: 4 Weeks|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement of morning peak expiratory flow over first 2 weeks |  |  |
Fear of Cancer Recurrence in Genitourinary Cancer

Study Overview
=================
Brief Summary
-----------------
To perform an analysis of independent predictors of fear of cancer recurrence in patients with malignant genitourinary diseases and their impact on quality of life and survival

Official Title
-----------------
Fear of Cancer Recurrence in Malignant Diseases of the Genitourinary Tract

Conditions
-----------------
Fear of Cancer Recurrence, Prostate Cancer, Renal Cell Cancer, Urothelial Carcinoma, Testicle Cancer

Intervention / Treatment
-----------------
* Other: FCR7 questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: histologically confirmed diagnosis of either prostate, urothelial cell, testicular or renal cell cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Prostatectomy<br>FCR7 questionnaire pre and postoperative | Other: FCR7 questionnaire<br>* A 7 item questionnaire about fear of cancer recurrence<br>|
| Cystectomy<br>FCR7 questionnaire pre and postoperative, 6 months follow | Other: FCR7 questionnaire<br>* A 7 item questionnaire about fear of cancer recurrence<br>|
| Nephrectomy<br>FCR7 questionnaire pre and postoperative | Other: FCR7 questionnaire<br>* A 7 item questionnaire about fear of cancer recurrence<br>|
| Orchidectomy<br>FCR7 questionnaire pre and postoperative | Other: FCR7 questionnaire<br>* A 7 item questionnaire about fear of cancer recurrence<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in fear of cancer recurrence pre- and postoperatively | Changes in the FCR7 score pre- and postoperatively | 7 to 10 days after initial surgery |
Laser Acupuncture in Rheumatoid Arthritis Geriatric Patients

Study Overview
=================
Brief Summary
-----------------
Studying the effect of laser acupuncture on geriatric patients with rheumatoid arthritis

Official Title
-----------------
Laser Acupuncture in Rheumatoid Arthritis Geriatric Patients

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Combination Product: Laser, exercise, and methotrexate
* Combination Product: Exercise, and methotrexate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients referred from physician (immunologist) diagnosed with rheumatoid arthritis. Exclusion Criteria: Patients having the disease overlapping with other connective tissue diseases, such as systematic lupus erythromatosus and systematic sclerosis. History of malignancies.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Laser acupuncture and aerobic exercise<br> | Combination Product: Laser, exercise, and methotrexate<br>* Laser therapy at acupuncture points, aerobic exercise, and methotrexate<br>|
| Experimental: Aerobic exercise<br> | Combination Product: Exercise, and methotrexate<br>* Aerobic exercise, and methotrexate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Interleukin 6 (IL-6) | interleukin 6 | Baseline | 
| Interleukin 6 (IL-6) | interleukin 6 | 4 weeks | 
| Malondialdehyde (MDA) | malondialdehyde | Baseline | 
| Malondialdehyde (MDA) | malondialdehyde | 4 weeks | 
| Adenosine Triphosphate (ATP) | adenosine triphosphate | Baseline | 
| Adenosine Triphosphate (ATP) | adenosine triphosphate | 4 weeks | 
| C-Reactive Protein (CRP) | C-reactive protein | Baseline | 
| C-Reactive Protein (CRP) | C-reactive protein | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rheumatoid Arthritis Quality of Life (RAQoL) | rheumatoid arthritis quality of life | Baseline | 
| Rheumatoid Arthritis Quality of Life (RAQoL) | rheumatoid arthritis quality of life | 4 weeks | 
| Health Assessment Questionnaire (HAQ) | health assessment questionnaire | Baseline | 
| Health Assessment Questionnaire (HAQ) | health assessment questionnaire | 4 weeks |
Correlation OF Hemodynamics in Pulmonary Hypertension With Perfusion Lung Scans

Study Overview
=================
Brief Summary
-----------------
The goal of our study is to correlate data from non-invasive tests such as perfusion lung scans with hemodynamic measurements from right heart catherizations.

Detailed Description
-----------------
Data collected from PAH patients who have had non-invasive Ventilation/Perfusion testing, Echocardiography, Chest CT Scan, Pulmonary Function Testing and the correlation of those results to the hemodynamic parameters Right Heart Catherization results and the various biomarkers.

Official Title
-----------------
Correlation of Hemodynamics in Pulmonary Hypertension With Perfusion Lung Scans

Conditions
-----------------
Pulmonary Arterial Hypertension

Intervention / Treatment
-----------------
* Other: Pulmonary Arterial Hypertension - Lung Perfusion Scans


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pulmonary Arterial Hypertension Exclusion Criteria: Non-Pulmonary Arterial Hypertension

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Pulmonary Arterial Hypertension | Other: Pulmonary Arterial Hypertension - Lung Perfusion Scans<br>* Correlation of data from non-invasive tests such as lung perfusion scans with hemodynamic measurements<br>* Other names: Pulmonary Arterial Hypertension;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The correlation of patients' hemodynamic parameters with their perfusion index/pulmonary index as measured by ventilation perfusion scans in patients diagnosed with Pulmonary Hypertension. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PAH; V/Q SCAN;RHC;Echo;CT Scans; Angiography;PFTs
Central Venous Catheter Lock Solution

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the application of 47% citrate lock solution decreases the incidence of infection and thrombosis of central venous catheter in hemodialysis population.

Official Title
-----------------
Randomized Control Trial on Citrate as the Central Venous Catheter Lock Solution

Conditions
-----------------
Bacteremia

Intervention / Treatment
-----------------
* Other: citrate
* Other: heparin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of end stage renal disease Exclusion Criteria: Patients refusing randomization
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: citrate<br> | Other: citrate<br>* comparison of different catheter lock solutions<br>|
| Active Comparator: heparin<br> | Other: heparin<br>* comparison of different lock solutions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lower incidence of infection |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lower incidence of thrombosis |  | 1 year |